All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2022-04-29T13:17:31.000Z

Frontline ponatinib with steroids for patients with Ph+ ALL

By Claire Baker, Suzie de Barra
Apr 29, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL

Bookmark this article

The ALL Hub is pleased to present a visual abstract representing key data from the phase II INCB84344-201 trial (NCT01641107) evaluating ponatinib plus prednisone as a firstline treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) who are aged ≥60 years or considered ineligible for intensive chemotherapy and stem cell transplantation.


 

More about...
Philadelphia chromosome-positive / BCR-ABL1PonatinibTyrosine kinase inhibitors

Your opinion matters

HCPs, what is your preferred format for educational content on the ALL Hub?
6 votes - 49 days left ...

Related articles

Add bookmark

U.S. FDA approves ponatinib plus chemotherapy for adult patients with newly diagnosed Ph+ ALL

Following positive response data from the phase III PhALLCON study, ponatinib plus chemotherapy receives accelerated U.S. FDA approval for the treatment of...

Mar 20, 2024
Add bookmark

U.S. FDA approves ponatinib plus chemotherapy for adult patients with newly diagnosed Ph+ ALL

Following positive response data from the phase III PhALLCON study, ponatinib plus chemotherapy receives...

Mar 20, 2024
Add bookmark

Pre-emptive versus prophylactic use of TKIs after allo-SCT in patients with Philadelphia chromosome-positive ALL

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion gene product have revolutionized therapy for patients with...

Jul 28, 2021
Add bookmark

Pre-emptive versus prophylactic use of TKIs after allo-SCT in patients with Philadelphia chromosome-positive ALL

Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion gene product have...

Jul 28, 2021

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox